Home » Nevro Receives FDA Approval to Initiate U.S. Randomized Pivotal Trial of Innovative Chronic Pain Treatment
Nevro Receives FDA Approval to Initiate U.S. Randomized Pivotal Trial of Innovative Chronic Pain Treatment
Nevro announced that the FDA has granted approval for initiation of its SENZA-RCT study evaluating the safety and efficacy of Nevro’s high-frequency spinal cord stimulation system for the treatment of chronic pain.
SYS-CON Media
SYS-CON Media
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May